Grants and Contributions:
Title:
ARP - Next Generation treatment delivery based on smart material
Agreement Number:
902664
Agreement Value:
$50,000.00
Agreement Date:
Apr 1, 2018 - Jan 4, 2019
Description:
In-vitro development of next generation glucose-sensitive implantable device for diabetes treatment based on smart sol-gel.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Montreal, Quebec, CA H4P 2R2
Reference Number:
172-2018-2019-Q1-902664
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
819762410
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 65 days.
Amendment Date
Oct 23, 2018
Recipient's Legal Name:
Bioastra Technologies inc.
Federal Riding Name:
Mount Royal
Federal Riding Number:
24052
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
313320
Amendments: